Cytomegalovirus (CMV) has been recognized as one of the most important opportunistic pathogens in transplant recipients. The aim of this study is to describe the patient characteristics, clinical presentations, the diagnostic tools, therapeutic regimens and outcomes of the CMV infections in solid organ recipients. Medical records of patients were evaluated retrospectively. Twenty one CMV infection episodes in 20 solid organ recipients who were followed with the diagnosis of CMV infection during the period 1997-2007 in our transplantation center were included. Fourteen of the patients were male and 6 were female. One of the 14 male patients and 2 of the 6 female patients were liver recipients and the remaining 17 were kidney recipients. Fourteen episodes in 13 patients were CMV gastritis and/or colitis; five were CMV syndrome without end-organ disease. Two end organ involvements were seen in the remaining patient; CMV pneumonia and colitis. Histopathological diagnosis was available for 15 of the episodes along with CMV PCR or CMV pp65 antigenemia. The remaining five episodes were diagnosed with CMV PCR or CMV pp65 antigenemia. All patients were treated with intravenous gancyclovir for 2-4 weeks. All patients responded to therapy and survived. Major advances have been achieved regarding the management of CMV infection and disease. These advances have been made possible through the development of new techniques for the detection of the virus. CMV pp65 antigenemia testing or CMV PCR is useful for surveillance of active infection. As a result of prevention and treatment of CMV infection, both the direct and indirect effects secondary to CMV replication have led to improved outcomes.